Latest News

Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028




SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, €450.0 million in aggregate principal amount ($492.8 million U.S. dollar

Source link




Related posts

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

Newsemia

Concept design of the LiteBIRD satellite for CMB B-mode polarization

Newsemia

New Technique Causes Cancer To Self-Destruct

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy